Bayer Aktiengesellschaft

Other

Graham Sturton

Mary F Fitzgerald

Mazen Es-Sayed

Trevor S Abram

Karl-Heinz Schlemmer

Rolf Henning

Michael Sperzel

Stephen Richard Tudhope

Rudiger Fischer

Rudolf H Hanko

Gabriele Braunlich

Ulrich Nielsch

Gabriele Br&auml;unlich

R&uuml;diger Fischer

Wendy J McDonald-Gibson

Hilmar Bischoff

Cristina Alonso-Alija

Nils Burkhardt

Nigel J Cuthbert

Burkhard Fugmann

Stephan Schneider

Volker Geiss

Arnel B Concepcion

Barbara Briggs

Elisabeth Perzborn

Klaus Sasse

Friedel Seuter

Martin Hendrix

Bernd Riedl

Helmut Haning

Klaus-Helmut Mohrs

Dagmar Karthaus

William H Bullock

Heike Gielen-Haertwig

Bernhard Pelster

Maria Niewöhner, Legal Representative

Maria Niewöhner

Kevin Nash

Dagmar Schauss

Martin Michels

Heike Gielen

Steve Tudhope

John-Edward Butler-Ransohoff

R Udiger Fischer

Gabriele Br Aunlich

Burkhardt Fugmann

Philip J Gardiner

Michael Hammond

Günter Benz

Gabriele Br{umlaut Over (a)}unlich

Lorenz Mayr

The invention relates to 7-(4-tert butyl-cyclohexyl)-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.

Heterocycles 3

The invention relates to novel 5-ethyl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.

5-ethylimidarotriazones

Novel 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives, use of substituted 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives as Matrix Metalloprotease Inhibitors for the Treatment of Respiratory Diseases, pharmaceutical compositions containing them, and a process for using them. The compounds of the invention have the generalized formula (I) (T)A&#x2014;B&#x2014;D&#x2014;E&#x2014;COH wherein A is an aryl or heteroaryl rings; B is an aryl or heteroaryl ring or a bond; each T is a substituent group, x is 0, 1, or 2; the group D represents (a), (b), (c), or (d); the group E represents a two or three carbon chain bearing one to three substituent groups which are independent or are involved in ring formation, possible structures being shown in the text and claims; and each of the substituents on E is an independent substituent; and include pharmaceutically acceptable salts thereof.

Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases

N-(3-benzofuranyl)urea-derivatives are prepared by reacting of 3-amino-substituted benzofuranes with appropriate substituted isocyanates or isothiocyanates. The N(3-benzofuranyl)urea-derivatives can be used as active ingredients in medicaments particularly for the treatment of acute and chronic inflammatory processes.

N-(3-benzofuranyl)urea-derivatives

Benzofuranylsulfonates

N-(3-benzofuranyl) urea-derivatives

3-Urea-pyridofurans and -pyridothiophenes are prepared by reacting appropriately substituted 3-amino-pyridofurans or -pyridothiophenes with isocyanates or isothiocyanates. The 3-urea-pyridofurans and -pyridothiophenes can be used as active ingredients in medicaments, particularly in medicaments for the treatment of acute and chronic inflammatory processes.

3-Ureido-pyridofurans and -pyridothiophenes for the treatment of inflammatory processes

Heterocyclyclcarbonyl substituted benzofuranyl-ureas are prepared by reacting heterocyclylcarbonyl substituted 3-amino-benzofuranes with appropriate isocyanates or isothiocyanates. The unsubstituted ureas are transferred into substituted ureas by usual methods of substitution. The heterocyclylcarbonyl substituted benzofuranyl-ureas are useful as active ingredients in medicaments particularly for the treatment of acute and chronical inflammatory processes.

Heterocyclylcarbonyl substituted benzofuranyl-ureas

Heterocyclylcarbonyl substituted benzofuranyl- and thiophenyl-alkanecarboxylic acid derivatives are prepared by reacting appropriately substituted hydroxybenzene butanoic acid esters with heterocyclic ketones. The inventive compounds can be used for the preparation of medicaments, particularly of medicaments for the treatment and prevention of acute and chronic inflammatory processes.

Heterocyclylcarbonyl substituted benzofuranyl- and

6-Amino-benzofuryl- and thienyl-derivatives can be prepared by reacting appropriate amino-substituted benzoyl phenols with appropriate substituted acetophenones and subsequent modification of the substituents. The compounds are useful for the treatment of actual and chronic inflammatory diseases, particularly of the airways and the gastro-intestinal tract.

Amino-benzofuryl-and thienyl-derivatives

The inventive Oxalylamino-benzofuran- and benzothienyl-derivatives are prepared by reacting the appropriate amino substituted benzofuranes and benzothiophenes with oxalic acid derivatives. The inventive compounds are suitable for the prevention and treatment of acute and chronic inflammatory processes, particularly of the airways.

Oxalylamino-benzofuran- and benzothienyl-derivatives

The Benzofuranyl- and -thiophenyl-alkane-carboxylic acid derivatives are prepared Tby cyclisation of hydroxy acetophenones and related compounds or by Wittig-reaction of benzofuranyl aldehydes. The compounds can be used to prepared medicaments.

Benzofuranyl-and-thiophenyl-alkanecarboxyclic acid derivatives

The invention relates to 1-heteroaryl-4-aryl-pyrazolin-5-ones, a preparation process and the use in combating diseases, in particular for use as lipoxygenase inhibitors.

1-Heteroaryl-4-aryl-pyrazolin-5-ones for use as medicaments

Growing community of inventors

Bray Maidenhead, United Kingdom

Graham Sturton